These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15897249)

  • 21. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
    Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
    Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines.
    Yamamoto K; Iwahana M; Kumazawa E; Kakihata K; Abe K; Hirano F; Tohgo A; Hoshiai H; Noda K
    Oncol Rep; 2003; 10(3):593-8. PubMed ID: 12684629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
    Nakajima TE; Yasunaga M; Kano Y; Koizumi F; Kato K; Hamaguchi T; Yamada Y; Shirao K; Shimada Y; Matsumura Y
    Int J Cancer; 2008 May; 122(9):2148-53. PubMed ID: 18196580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
    Vassal G; Boland I; Santos A; Bissery MC; Terrier-Lacombe MJ; Morizet J; Sainte-Rose C; Lellouch-Tubiana A; Kalifa C; Gouyette A
    Int J Cancer; 1997 Sep; 73(1):156-63. PubMed ID: 9334824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antitumor effect of CPT-11, a camptothecin derivative, on human testicular tumor xenografts in nude mice.
    Miki T; Sawada M; Nonomura N; Kojima Y; Okuyama A; Maeda O; Saiki S; Kotake T
    Eur Urol; 1997; 31(1):92-6. PubMed ID: 9032542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
    Ishiguro M; Iida S; Uetake H; Morita S; Makino H; Kato K; Takagi Y; Enomoto M; Sugihara K
    Ann Surg Oncol; 2007 May; 14(5):1752-62. PubMed ID: 17195906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
    Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A
    Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.
    Kudoh S; Takada M; Masuda N; Nakagawa K; Itoh K; Kusunoki Y; Negoro S; Matsui K; Takifuji N; Morino H
    Jpn J Cancer Res; 1993 Feb; 84(2):203-7. PubMed ID: 8385085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Bissery MC; Vrignaud P; Lavelle F; Chabot GG
    Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
    Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
    Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer.
    Mercalli A; Sordi V; Formicola R; Dandrea M; Beghelli S; Scarpa A; Di Carlo V; Reni M; Piemonti L
    Br J Cancer; 2007 May; 96(9):1358-67. PubMed ID: 17426706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
    Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
    Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
    Chen TC; Su S; Fry D; Liebes L
    Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
    Jansen WJ; Kolfschoten GM; Erkelens CA; Van Ark-Otte J; Pinedo HM; Boven E
    Int J Cancer; 1997 Dec; 73(6):891-6. PubMed ID: 9399672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
    Allegrini G; Di Paolo A; Cerri E; Cupini S; Amatori F; Masi G; Danesi R; Marcucci L; Bocci G; Del Tacca M; Falcone A
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):585-93. PubMed ID: 16680463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer.
    Miyaki Y; Suzuki K; Koizumi K; Kato T; Saito M; Kamiyama H; Maeda T; Shibata K; Shiya N; Konishi F
    Int J Oncol; 2012 Jan; 40(1):217-26. PubMed ID: 21901246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
    Cao S; Durrani FA; Toth K; Rustum YM; Seshadri M
    Oral Oncol; 2011 Jun; 47(6):459-66. PubMed ID: 21530364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.